Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Sturdy third quarter performance facilitated the shares of Companhia de Bebidas Das Americas (ABV - Analyst Report), alias AmBev, to reach a new 52-week high of $45.84 on Friday, Jan 25, beating its previous 52-week high of $45.62. This Zacks Rank #2 (Buy) Brazilian beer giant represented a healthy return of 14.9% over the past six months. Average volume of shares traded over the last 3 months stands at approximately 1,785,400.
Drivers that Triggered Momentum
An impressive third quarter beat, improved margins and strong financial position are the attributes that pushed the shares of AmBev to a new high.
AmBev reported robust third-quarter 2012 normalized earnings of R$0.81 per share, substantially beating the prior-year quarter’s earnings of R$0.53 by 52.6%. The results were primarily driven by solid top-line performance, higher margins and lower tax rate. In the U.S. dollar terms, earnings came at 39 cents per share, which beat the Zacks Consensus Estimate of 35 cents.
Reported net sales increased 26.1% to R$8.036 billion compared with R$6.375 billion in the prior-year quarter. The increase in revenues was primarily attributable to a marginal hike of 1.5% in volumes across all regions. On an organic basis, total revenue jumped 15.1% from the prior-year quarter despite a 0.5% decline in overall organic volume.
In spite of the input cost pressure, organic gross profit escalated 17.1% to R$5.414 billion compared with R$4.244 billion in the year-ago quarter. Gross profit margin expanded 120 basis points (bps) organically to 67.4%, primarily driven by margin expansion at every business unit.
AmBev’s financial position remained strong at the end of the quarter with cash and cash equivalents of R$4.531 billion and shareholders’ equity of R$27.496 billion. The company generated R$4.366 billion of cash from its operating activities. Moreover, it paid a dividend and IOC of R$1.2 billion to its shareholders during the quarter.
Besides AmBev, other beverage-alcohol companies like Constellation Brands Inc. (STZ - Analyst Report), Brown-Forman Corporation (BF.B - Analyst Report) and Beam Inc. (BEAM - Snapshot Report) posted robust earnings results in the recently reported quarters.
Stock’s Key Indicators
AmBev currently trades at a forward P/E of 25.2x, 41.7% above the peer group average of 17.8x. Its price-to-sales ratio of 9.3x also remains substantially higher than the peer group average of 3.1x. Moreover, the company’s return-on-investment (ROI) and return-on-asset (ROA) are 34.3% and 19.9%, respectively, which are significantly higher than the peer group average.
Get the full Analyst Report on BF.B - FREE
Get the full Analyst Report on STZ - FREE
Get the full Analyst Report on ABV - FREE
Get the full Snapshot Report on BEAM - FREE